Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Ja, Decaprio"'
Autor:
Urashima M, Teoh G, Atsushi Ogata, Chauhan D, Sp, Treon, Sugimoto Y, Kaihara C, Matsuzaki M, Hoshi Y, Ja, Decaprio, Kc, Anderson
Publikováno v:
Europe PubMed Central
Loss of p16(INK4A) (p16) expression is frequently associated with the development of epithelial and lymphoid malignancies. However, the frequency and significance of p16 abnormalities in multiple myeloma (MM) and the more aggressive phase of plasma c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4fb5120d01aea8c5459566f94a5ef925
https://pubmed.ncbi.nlm.nih.gov/9815612
https://pubmed.ncbi.nlm.nih.gov/9815612
Publikováno v:
Europe PubMed Central
Homozygous p16(INK4A) (p16) gene deletion is frequent in primary tumor cells from acute lymphoblastic leukemia (ALL), suggesting that loss of p16 may be an important precursor to transformation in ALL. We have previously described JKB, a human ALL ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7d9b9c17bf69b9e99f553b2cc4b6bad7
https://pubmed.ncbi.nlm.nih.gov/9354681
https://pubmed.ncbi.nlm.nih.gov/9354681
Autor:
Teoh G, Urashima M, Atsushi Ogata, Chauhan D, Ja, Decaprio, Sp, Treon, Rl, Schlossman, Kc, Anderson
Publikováno v:
Europe PubMed Central
The murine double minute 2 (MDM2) protein facilitates G1 to S phase transition by activation of E2F-1 and can enhance cell survival by suppressing wild-type p53 (wtp53) function. In this study, we examined MDM2 expression and function in multiple mye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3b727c4c97cd2b54aca321ba352c5b1e
https://pubmed.ncbi.nlm.nih.gov/9292533
https://pubmed.ncbi.nlm.nih.gov/9292533
Autor:
Urashima M, Hoshi Y, Sugimoto Y, Kaihara C, Matsuzaki M, Chauhan D, Atsushi Ogata, Teoh G, Ja, Decaprio, Kc, Anderson
Publikováno v:
Europe PubMed Central
p16 INK4A and/or p15 INK4B genes are frequently deleted in leukemias and other cancers. We have established a novel pre-B acute lymphoblastic leukemia (ALL) cell line (JKB2) with a chromosomal translocation between 9p2l and 14q32, on which p16INK4A/p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::87b2d1a538445a5043365babb85d1880
https://pubmed.ncbi.nlm.nih.gov/8847892
https://pubmed.ncbi.nlm.nih.gov/8847892
Autor:
Urashima M, Atsushi Ogata, Chauhan D, Mb, Vidriales, Teoh G, Hoshi Y, Rl, Schlossman, Ja, Decaprio, Kc, Anderson
Publikováno v:
Europe PubMed Central
Interleukin-6 (IL-6) mediates autocrine and paracrine growth of multiple myeloma (MM) cells and inhibits tumor cell apoptosis. Abnormalities of retinoblastoma protein (pRB) and mutations of RB gene have been reported in up to 70% of MM patients and 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::40199cd947e02102d6d7a8afb8e63cca
http://europepmc.org/abstract/med/8822942
http://europepmc.org/abstract/med/8822942
Autor:
Booth CA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Bouyssou JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Togami K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Armand O; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Rivas HG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA., Yan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Rice S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Cheng S; Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Molecular Pharmacology Program, Sloan Kettering Institute, New York, New York, USA.; Departments of Pediatrics, Pharmacology, and Physiology & Biophysics, Weill Medical College of Cornell University, New York, New York, USA., Lachtara EM; Krantz Family Center for Cancer Research, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Bourquin JP; Division of Oncology, Children's Research Center, University Children's Hospital, Zurich, Switzerland., Kentsis A; Tow Center for Developmental Oncology, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Molecular Pharmacology Program, Sloan Kettering Institute, New York, New York, USA.; Departments of Pediatrics, Pharmacology, and Physiology & Biophysics, Weill Medical College of Cornell University, New York, New York, USA., Rheinbay E; Krantz Family Center for Cancer Research, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Lane AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
JCI insight [JCI Insight] 2024 Dec 20; Vol. 9 (24). Date of Electronic Publication: 2024 Dec 20.
Autor:
Bahar F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
The British journal of dermatology [Br J Dermatol] 2024 May 17; Vol. 190 (6), pp. 785-786.
Autor:
Choudhury R, Bonacci T, Arceci A, Lahiri D, Mills CA, Kernan JL, Branigan TB, DeCaprio JA, Burke DJ, Emanuele MJ
Publikováno v:
Cell reports [Cell Rep] 2024 Mar 26; Vol. 43 (3), pp. 113974. Date of Electronic Publication: 2024 Mar 07.
Autor:
Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Davidsohn MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Fortunato B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Semaan K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Sotudian S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Lakshminarayanan G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Diossy M; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., El Zarif T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Savignano H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Canniff J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Madueke I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Saliby RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Zhang Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA., Li R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Jiang Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Taing L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Awad M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chau CH; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Figg WD; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Greten TF; Liver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hata AN; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hughes ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ng K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Meador C; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Parsons HA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Rajan A; Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thakuria M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Berchuck JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Szallasi Z; Computational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.; Danish Cancer Institute, Copenhagen, Denmark.; Department of Bioinformatics and Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.; Eli and Edythe L. Broad Institute, Cambridge, MA, USA. matthew_freedman@dfci.harvard.edu.
Publikováno v:
Nature medicine [Nat Med] 2024 Mar; Vol. 30 (3), pp. 907.
Autor:
Martins C; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Rasbach E; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Surgery, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany., Heppt MV; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University (FAU), 91054 Erlangen, Germany., Singh P; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Kulcsar Z; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Dermatology, University Hospital Bonn, 53127 Bonn, Germany., Holzgruber J; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Dermatology and Venerology, Johannes Kepler University, 4020 Linz, Austria., Chakraborty A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Mucciarone K; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Kleffel S; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Brandenburg A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Dermatology, University Hospital Bonn, 53127 Bonn, Germany., Hoetzenecker W; Department of Dermatology and Venerology, Johannes Kepler University, 4020 Linz, Austria., Rahbari NN; Department of Surgery, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany., DeCaprio JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.; Program in Virology, Graduate School of Arts and Sciences, Harvard University, Cambridge, MA 02138, USA.; Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham and Women's Hospital Cancer Center, Boston, MA 02115, USA., Thakuria M; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham and Women's Hospital Cancer Center, Boston, MA 02115, USA., Murphy GF; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Ramsey MR; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Posch C; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Dermatology, Vienna Healthcare Group, 1130 Vienna, Austria.; Faculty of Medicine, Sigmund Freud University Vienna, 1020 Vienna, Austria.; Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, 81675 Munich, Germany., Barthel SR; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Schatton T; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Program of Glyco-Immunology and Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Department of Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Publikováno v:
Science advances [Sci Adv] 2024 Jan 19; Vol. 10 (3), pp. eadi2012. Date of Electronic Publication: 2024 Jan 19.